Long-Term Zoledronic Acid Treatment Increases Bone Structure and Mechanical Strength of Long Bones of Ovariectomized Adult Rats

2003 ◽  
Vol 72 (4) ◽  
pp. 519-527 ◽  
Author(s):  
S.B. Hornby ◽  
G.P. Evans ◽  
S.L. Hornby ◽  
A. Pataki ◽  
M. Glatt ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Mechanical Strength ◽  
Acid Treatment ◽  
Bone Structure ◽  
Long Bones ◽  
Adult Rats ◽  
Ovariectomized Adult Rats

scholarly journals Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease

2017 ◽  
Vol 8 (6) ◽  
pp. 294-302 ◽  
Author(s):  
Giampiero I. Baroncelli ◽  
Elena Ferretti ◽  
Cecilia M. Pini ◽  
Benedetta Toschi ◽  
Rita Consolini ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Turnover ◽  
Acid Treatment ◽  
Clinical Symptoms ◽  
Severe Form ◽  
Bone Lesions ◽  
Engelmann Disease

scholarly journals Effects of Bisphosphonates on Osseointegration of Dental Implants in Rabbit Model

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Ru Qing Yu ◽  
Jing Yi Wang ◽  
Nian Jing Rao ◽  
Lei Huo ◽  
Li Wu Zheng
Keyword(s):  
Zoledronic Acid ◽  
Dental Implants ◽  
Dental Implant ◽  
Growth Rates ◽  
Acid Treatment ◽  
Bone Growth ◽  
Rabbit Model ◽  
Short Term ◽  
Calvarial Bone

This study is to investigate the effect of bisphosphonates on the osseointegration of dental implants in a rabbit model. Twenty female New Zealand White rabbits were equally assigned into control and experiment groups which received saline or zoledronic acid treatment 4 weeks prior to surgery. Titanium dental implant was placed on the calvarial bone. Zoledronic acid or saline treatment continued after surgery for 4 weeks (short-term subgroup) or 8 weeks (long-term subgroup) until sacrifice. Three different fluorochrome labeling solutions were administrated for assessing bone growth rates. Samples of the calvarial bone and mandible were subjected to microcomputed tomography (micro-CT), confocal microscope, and histology analysis. Zoledronic acid treatment significantly reduced bone growth rates in the calvarial bone, but had no significant influence in bone mineral density and trabecular microarchitecture. Significantly lower bone-to-implant contact ratios were found in zoledronic acid-treated animals compared to controls at week 4 but not at week 8. Oncologic dose zoledronic acid suppresses the bone growth rates of the calvarial bone; ZA may have an adverse effect on osseointegration of dental implant in short term, but this effect tends to diminish in long term.

Effects of Catecholestrogens on Luteinizing Hormone Levels in Long Term Ovariectomized Adult Rats*

Endocrinology ◽  
1981 ◽  
Vol 109 (4) ◽  
pp. 1037-1039 ◽  
Author(s):  
PETER BALL ◽  
GüNTER EMONS ◽  
THOMAS KLINGEBIEL ◽  
KATHRIN-MARIA GRüHN ◽  
RUDOLF KNUPPEN
Keyword(s):  
Luteinizing Hormone ◽  
Adult Rats ◽  
Hormone Levels ◽  
Ovariectomized Adult Rats

scholarly journals Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Momoko Takahashi ◽  
Yukinori Ozaki ◽  
Rika Kizawa ◽  
Jun Masuda ◽  
Kentaro Sakamaki ◽  
...  
Keyword(s):  
Risk Factors ◽  
Zoledronic Acid ◽  
Bone Metastasis ◽  
Femoral Fracture ◽  
Acid Treatment ◽  
Atypical Femoral Fracture ◽  
Study Population ◽  
Skeletal Related Events ◽  
Denosumab Treatment

Abstract Background While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF). While AFF has been reported in patients with osteoporosis receiving denosumab, data are scarce in the context of AFF occurring in patients with bone metastasis receiving monthly denosumab therapy. Methods To analyze the incidence of AFF in patients with bone metastasis, we reviewed the medical records of patients who had received monthly denosumab (120 mg) treatment from May 2012 to June 2017 at any of the three participant institutions. Results The study population consisted of 277 patients who had received a median of 10 doses (range, 1–79) of denosumab. Five patients were diagnosed as having AFF or symptomatic atypical femoral stress reaction (AFSR) needing surgical intervention, representing an incidence rate of 1.8% (95% confidence interval, 0.77–4.2). These patients had received 15, 45, 45, 46 or 47 doses of denosumab, respectively. Four of the patients had received prior zoledronic acid treatment. The results of our analysis suggested that long-term use of denosumab, especially for more than 3.5 years, and prior use of zoledronic acid were risk factors for the development of AFF. Conclusions We found the AFF events in 5 patients (1.8%) among 277 cancer patients who had received monthly denosumab (120 mg) treatment. Long-term denosumab treatment and prior zoledronic acid treatment were identified as risk factors for the development of AFF.

scholarly journals Bilateral femoral head osteonecrosis in a patient with metastatic breast cancer receiving long‑term zoledronic acid treatment: A case report

2021 ◽  
Vol 15 (2) ◽  
Author(s):  
Kazuo Matsuura ◽  
Toshiaki Saeki ◽  
Takao Takahashi ◽  
Tomoaki Torigoe ◽  
Keisuke Watarai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Zoledronic Acid ◽  
Femoral Head ◽  
Acid Treatment ◽  
Metastatic Breast ◽  
Femoral Head Osteonecrosis

Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid

2004 ◽  
Vol 15 (9) ◽  
Author(s):  
Markus Glatt ◽  
Alexander Pataki ◽  
G.Paul Evans ◽  
SimonB. Hornby ◽  
JonathanR. Green
Keyword(s):  
Zoledronic Acid ◽  
Mechanical Strength ◽  
Vertebral Bone ◽  
Term Administration
Sign in / Sign up

Export Citation Format

Share Document